ArticleInternational urology and nephrology2026
Wearable technology-derived digital biomarkers for non-invasive assessment of erectile dysfunction: a cross-sectional pilot study.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionErectile dysfunction (ED) represents a significant health concern that affects not only physical well-being but also psychological health and quality of life. This study aimed to investigate the potential of digital biomarkers derived from smartwatches for the risk assessment of ED.
methodsThis prospective, comparative cross-sectional study investigated digital biomarkers derived from smartwatch technology for ED assessment in 74 male participants (38 ED patients, 36 controls) between May and September 2025. Participants wore iOS-based smartwatches continuously for 14 days to monitor physiological parameters including heart rate variability (HRV), sleep architecture, and physical activity levels. ED diagnosis was established using the International Index of Erectile Function 5-item form (IIEF-5) with scores ≤ 21 indicating ED. Statistical analyses included univariate/multivariate logistic regression and ROC curve analysis.
resultsCompared to controls, the ED group demonstrated significantly lower HRV (32 vs. 38.5 ms, p < 0.001), higher resting heart rate (69 vs. 58 bpm, p < 0.001), increased wake time percentage (p < 0.001), decreased deep sleep duration (20% vs. 25%, p < 0.001), and reduced daily step count (4196 vs. 5142 steps, p = 0.001). Multivariate analysis identified HRV (OR: 0.884, p = 0.019), wake time percentage (OR: 1.832, p = 0.005), and daily step count (OR: 0.872, p = 0.002) as independent associated variables. ROC analysis revealed wake time percentage demonstrated highest screening performance (AUC: 0.752, sensitivity: 68.4%, specificity: 69.4%).
conclusionPreliminary findings from this pilot study suggested that digital biomarkers from smartwatch technology could offer potential for non-invasive ED risk assessment. These results provided a feasibility foundation for integrating wearable technologies into clinical practice for personalized sexual health management.
Indexed as
Identifiers
41499059What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.